Charles River Laboratories International, Inc. (NYSE:CRL) – SunTrust Banks lowered their Q3 2017 earnings estimates for Charles River Laboratories International in a note issued to investors on Thursday. SunTrust Banks analyst S. Draper now forecasts that the medical research company will earn $1.21 per share for the quarter, down from their prior estimate of $1.25. SunTrust Banks also issued estimates for Charles River Laboratories International’s Q4 2017 earnings at $1.34 EPS, FY2018 earnings at $5.73 EPS and FY2019 earnings at $6.41 EPS.

Charles River Laboratories International (NYSE:CRL) last posted its quarterly earnings results on Wednesday, August 9th. The medical research company reported $1.29 EPS for the quarter, topping the consensus estimate of $1.22 by $0.07. Charles River Laboratories International had a return on equity of 27.02% and a net margin of 10.13%. The business had revenue of $469.13 million for the quarter, compared to analyst estimates of $458.25 million. During the same quarter in the previous year, the firm earned $1.20 EPS. The company’s quarterly revenue was up 8.1% compared to the same quarter last year.

ILLEGAL ACTIVITY WARNING: This news story was originally published by Daily Political and is owned by of Daily Political. If you are accessing this news story on another website, it was copied illegally and republished in violation of US and international copyright and trademark legislation. The correct version of this news story can be viewed at https://www.dailypolitical.com/2017/08/11/suntrust-banks-weighs-in-on-charles-river-laboratories-international-inc-s-q3-2017-earnings-crl.html.

Several other brokerages also recently issued reports on CRL. Zacks Investment Research downgraded Charles River Laboratories International from a “buy” rating to a “hold” rating in a research report on Tuesday, July 25th. Jefferies Group LLC reiterated a “buy” rating and set a $106.00 target price on shares of Charles River Laboratories International in a research report on Friday, April 21st. Citigroup Inc. reiterated a “neutral” rating and set a $104.00 target price (up from $90.00) on shares of Charles River Laboratories International in a research report on Thursday, May 11th. BidaskClub downgraded Charles River Laboratories International from a “strong-buy” rating to a “buy” rating in a research report on Monday, July 31st. Finally, Barclays PLC reiterated a “hold” rating and set a $102.00 target price on shares of Charles River Laboratories International in a research report on Wednesday, July 19th. One equities research analyst has rated the stock with a sell rating, four have assigned a hold rating and five have issued a buy rating to the stock. Charles River Laboratories International currently has a consensus rating of “Hold” and a consensus price target of $96.94.

Charles River Laboratories International (NYSE CRL) opened at 96.72 on Friday. The stock’s 50 day moving average price is $99.87 and its 200 day moving average price is $91.54. Charles River Laboratories International has a 12-month low of $67.20 and a 12-month high of $102.32. The stock has a market cap of $4.60 billion, a price-to-earnings ratio of 25.49 and a beta of 1.02.

Several institutional investors have recently added to or reduced their stakes in the company. Zurcher Kantonalbank Zurich Cantonalbank increased its position in Charles River Laboratories International by 12.7% in the second quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 1,791 shares of the medical research company’s stock worth $181,000 after buying an additional 202 shares during the period. Riverhead Capital Management LLC increased its position in Charles River Laboratories International by 14.7% in the second quarter. Riverhead Capital Management LLC now owns 1,931 shares of the medical research company’s stock worth $195,000 after buying an additional 247 shares during the period. Cambridge Advisors Inc. purchased a new position in Charles River Laboratories International during the second quarter worth approximately $202,000. Advisor Partners LLC purchased a new position in Charles River Laboratories International during the second quarter worth approximately $208,000. Finally, Campbell & CO Investment Adviser LLC purchased a new position in Charles River Laboratories International during the second quarter worth approximately $217,000. Institutional investors own 95.81% of the company’s stock.

In other news, insider David Ross Smith sold 945 shares of the firm’s stock in a transaction dated Thursday, June 8th. The stock was sold at an average price of $95.00, for a total value of $89,775.00. Following the transaction, the insider now directly owns 14,203 shares in the company, valued at approximately $1,349,285. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, Director George Massaro sold 3,830 shares of the firm’s stock in a transaction dated Monday, July 17th. The stock was sold at an average price of $100.81, for a total value of $386,102.30. Following the completion of the transaction, the director now owns 18,731 shares in the company, valued at $1,888,272.11. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 79,369 shares of company stock worth $7,846,412. Company insiders own 2.20% of the company’s stock.

Charles River Laboratories International declared that its board has approved a share repurchase program on Wednesday, May 10th that permits the company to repurchase $150.00 million in outstanding shares. This repurchase authorization permits the medical research company to repurchase shares of its stock through open market purchases. Stock repurchase programs are generally an indication that the company’s board of directors believes its stock is undervalued.

Charles River Laboratories International Company Profile

Charles River Laboratories International, Inc is an early-stage contract research company. The Company is engaged in laboratory animal medicine and science (research model technologies) and develop a portfolio of discovery and safety assessment services, both good laboratory practice (GLP) and non-GLP, which supports its clients from target identification through non-clinical development.

Earnings History and Estimates for Charles River Laboratories International (NYSE:CRL)

Receive News & Ratings for Charles River Laboratories International Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Charles River Laboratories International Inc. and related companies with MarketBeat.com's FREE daily email newsletter.